Leishmaniasis (Kala-azar) Drug Development Pipeline Study, H2 2018

August 2018 | 90 pages | ID: LC6A5BB53AEEN
VPAResearch

Abstracts

Leishmaniasis (Kala-azar) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Leishmaniasis (Kala-azar) pipeline products.

DISEASE OVERVIEW

Leishmaniasis is one of the most researched areas among infectious diseases. Over 33 companies are currently working on developing treatment options for visceral and cutaneous Leishmaniasis.

Leishmaniasis is a parasitic disease, caused by protozoan Leishmania parasites. In particular, female phlebotomine sand flies spread the virus.

According to W.H.O, around 0.7 million to 1 million new cases of Leishmaniasis are reported every year. Further, 20,000 to 30,000 of the patients die every year.

Three types of leishmaniases are identified – visceral (VL), cutaneous (CL) and mucocutaneous. Of these, Visceral or kala-azar is most dangerous while cutaneous is the most common type.

Visceral leishmaniasis (VL) is fatal in nature and occurs mostly in Brazil, East Africa and in South-East Asia. Cutaneous leishmaniasis (CL) is found mainly in Americas, the Mediterranean basin, the Middle East and Central Asia. Mucocutaneous leishmaniasis is often found in Bolivia, Brazil, Ethiopia and Peru.

REPORT DESCRIPTION

The Leishmaniasis (Kala-azar) pipeline guide presents complete overview of drugs currently being developed for Leishmaniasis (Kala-azar). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Leishmaniasis (Kala-azar) pipeline candidate.

Research and Development progress along with latest news related to each of the Leishmaniasis (Kala-azar) pipeline candidates is included.

Major companies participating in therapeutic development of Leishmaniasis (Kala-azar) are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Leishmaniasis (Kala-azar) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Leishmaniasis (Kala-azar) clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Leishmaniasis (Kala-azar) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF LEISHMANIASIS (KALA-AZAR) PIPELINE REPORT INCLUDES

• Panorama of Leishmaniasis (Kala-azar) pipeline markets including statistics on therapeutic drugs and companies involved
• Leishmaniasis (Kala-azar) Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
• Leishmaniasis (Kala-azar) pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
• Overview of companies participating in Leishmaniasis (Kala-azar) pipeline with short introduction to their businesses and pipeline projects
• For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
• Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Leishmaniasis (Kala-azar) pipeline therapeutics

REASONS TO BUY

• Get clear understanding of the entire Leishmaniasis (Kala-azar) pipeline, with details on active projects
• Get in detail information of each product with updated information on each project along with key milestones
• Know the list of companies participating in global Leishmaniasis (Kala-azar) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Leishmaniasis Pipeline include-
  Number of Companies with Leishmaniasis projects in pre-clinical Development-
  Number of Companies with Leishmaniasis projects in Clinical Development-
  Leishmaniasis Pipeline Companies based in Americas
  Leishmaniasis Pipeline Companies based in Europe
  Leishmaniasis Pipeline Companies based in Asia Pacific
  Leishmaniasis Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
  Leishmaniasis Pipeline Agents in pre- clinical/Discovery stage of Development
  Leishmaniasis Pipeline Agents in Clinical Development stage
  Leishmaniasis Pipeline Therapeutic Compounds received special status
  Mechanism of Action of most pipeline Drugs-
  Small molecules among the Leishmaniasis Pipeline agents

II. INSIGHTS INTO LEISHMANIASIS PIPELINE

1. Disease Overview
  Introduction to Leishmaniasis
  Symptoms and Causes of Leishmaniasis
  Treatment or Prevention Options for Leishmaniasis
  Other Details
2. Phase wise Pipeline Compounds
  Leishmaniasis Pipeline- Pre- Clinical/Discovery stage Drugs
  Leishmaniasis Pipeline- Phase 1 stage Drugs
  Leishmaniasis Pipeline- Phase 2 stage Drugs
  Leishmaniasis Pipeline- Phase 3 stage Drugs
  Leishmaniasis Pipeline- Pre-Registration stage Drugs
3. Company wise Leishmaniasis Pipeline Compounds
4. Leishmaniasis Pipeline by Mechanism of Action

III. LEISHMANIASIS PIPELINE COMPOUND DETAILS

18-MC
Drugs for Leishmaniasis
Aminopyrazoles
candicidin
CGH VL series
Corifungin
CPG-D35(CL)
D121
DNDI-0690 nitroimidazole
DNDI-5421
DNDI-5610
DNDI-6148 oxaborole
Drug for Leishmaniasis
Drug for Visceral Leishmaniasis
Drugs for Neglected Tropical Diseases
hypoestoxide
Leishmania DYRK1 homologue
LHR1 inhibitor
MGN1331
NanoDisk for leishmaniasis
NM147
oral Interferon-Gamma for Leishmaniasis
P-MAPA
small molecule for cutaneous leishmaniasis (CL)
SQ109
visceral leishmaniasis vaccine
Drug Details
1. Snapshot
  Name of the Therapeutic Agent
  Originator
  Developing Company
  Co-Developer/License Partner
  Orphan Drug/Fast Track/Designation
  Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. LEISHMANIASIS PIPELINE COMPANY BRIEFS

AbbVie Inc
Acea Biotech Inc
Advinus Therapeutics Ltd
Anacor Pharmaceuticals Inc
Anacor Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
BioLingus AG
Celgene Corporation
Daiichi Sankyo Co Ltd
DetectoGen Inc
Eisai Co Ltd
Epichem Pty Ltd
GlaxoSmithKline Plc
Immune Modulation Inc
Lypro Biosciences, Inc
ManRos Therapeutics SAS
Merck KGaA
Mologen AG
Nanomerics Ltd
Oblita Therapeutics bvba
Pfizer Inc
Rakta Therapeutics Inc
Savant HWP Inc
Sequella Inc
Shionogi & Co Ltd
Takeda Pharmaceutical Company Ltd

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL LEISHMANIASIS PIPELINE MARKET

VI. APPENDIX

1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability